Zealand Pharma A/S logo
Zealand Pharma A/S ZEAL

Annual report 2021
added 12-23-2023

report update icon

Zealand Pharma A/S Gross Profit 2011-2026 | ZEAL

Gross profit is a key indicator of how efficiently a company produces or sells its products. This metric helps assess a business’s ability to generate revenue at the initial stage, before accounting for all other expenses. Regular analysis of gross profit allows companies to respond in a timely manner to changes in cost of goods, pricing strategy, and market conditions.

Calculation formula:
Gross Profit = Revenue – Cost of Goods Sold (COGS)

Revenue — all cash inflows from the sale of goods or services.
Cost of Goods Sold — direct costs related to the production or acquisition of goods:
  • Raw materials and supplies
  • Wages of production personnel
  • Depreciation of equipment
  • Transportation and warehousing costs (if directly related to production)
Importance for business:
  • Assessing core business profitability
    If gross profit is declining, it may indicate rising production costs or falling sales.
  • Financial planning
    Gross profit is the basis for calculating other key metrics, such as operating and net profit.
  • Benchmarking against competitors
    Gross profit analysis helps compare the efficiency of different companies within the same industry.
  • Insights into pricing effectiveness
    If gross profit is low, the company may be pricing too low or failing to control costs effectively.
Reasons for a decline in gross profit:
  • Increase in raw material and supply costs
  • Rising production expenses
  • Price reductions due to competition
  • Decrease in sales volume
  • Currency exchange rate fluctuations (for imports/exports)

Gross profit is an important metric, but it does not provide a complete picture of a company’s financial health, as it does not account for administrative and selling expenses, taxes, debt burden, or depreciation.

Annual Gross Profit Zealand Pharma A/S

2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011
174 M 263 M 40.9 M -142 M 125 M 203 M 165 M 140 M 5.7 M 208 M 142 M

All numbers in DKK currency

Indicator range from annual reports

Maximum Minimum Average
263 M -142 M 120 M

Quarterly Gross Profit Zealand Pharma A/S

2022-Q4 2022-Q3 2022-Q2 2022-Q1 2021-Q4 2021-Q3 2021-Q2 2021-Q1 2020-Q4 2020-Q3 2020-Q2 2020-Q1 2019-Q4 2019-Q3 2019-Q2 2019-Q1 2018-Q4 2018-Q3 2018-Q2 2018-Q1 2017-Q4 2017-Q3 2017-Q2 2017-Q1 2016-Q4 2016-Q3 2016-Q2 2016-Q1 2015-Q4 2015-Q3 2015-Q2 2015-Q1 2014-Q4 2014-Q3 2014-Q2 2014-Q1 2013-Q4 2013-Q3 2013-Q2 2013-Q1 2012-Q4 2012-Q3 2012-Q2 2012-Q1 2011-Q4 2011-Q3 2011-Q2 2011-Q1
- - - - - - - - - 22.3 M - - - 9.69 M - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

All numbers in DKK currency

Indicator range from quarterly reporting

Maximum Minimum Average
22.3 M 9.69 M 16 M

Gross Profit of other stocks in the Biotechnology industry

Issuer Gross Profit Price % 24h Market Cap Country
MorphoSys AG MorphoSys AG
MOR
180 M - 2.43 % $ 254 M germanyGermany
Ascendis Pharma A/S Ascendis Pharma A/S
ASND
625 M $ 234.99 0.02 % $ 5 B danmarkDanmark
Acasti Pharma Acasti Pharma
ACST
-32.3 K - 4.01 % $ 150 M canadaCanada
Adverum Biotechnologies Adverum Biotechnologies
ADVM
2.32 M - - $ 86.2 M usaUSA
AgeX Therapeutics AgeX Therapeutics
AGE
102 K - -10.17 % $ 12.2 K usaUSA
AIkido Pharma AIkido Pharma
AIKI
10 K - 1.93 % $ 17.4 M usaUSA
Aptorum Group Limited Aptorum Group Limited
APM
-104 K $ 0.81 1.28 % $ 4.42 M chinaChina
argenx SE argenx SE
ARGX
2.68 M $ 840.28 1.7 % $ 25 B niderlandNiderland
Alexion Pharmaceuticals, Inc. Alexion Pharmaceuticals, Inc.
ALXN
5.52 B - - $ 40.3 B usaUSA
Albireo Pharma Albireo Pharma
ALBO
39.2 M - -0.23 % $ 916 M usaUSA
EyeGate Pharmaceuticals, Inc. EyeGate Pharmaceuticals, Inc.
EYEG
12.1 - -1.52 % $ 24.7 M usaUSA
Midatech Pharma plc Midatech Pharma plc
MTP
-428 K - -18.52 % $ 27.3 M britainBritain
Alterity Therapeutics Limited Alterity Therapeutics Limited
ATHE
177 K $ 3.33 0.79 % $ 8.01 B australiaAustralia
Ampio Pharmaceuticals Ampio Pharmaceuticals
AMPE
-523 K - -11.43 % $ 502 K usaUSA
Acorda Therapeutics Acorda Therapeutics
ACOR
119 M - -24.86 % $ 820 K usaUSA
Acer Therapeutics Acer Therapeutics
ACER
1.27 M - 2.71 % $ 14 M usaUSA
Aravive Aravive
ARAV
5.68 K - -13.39 % $ 1.45 M usaUSA
Институт стволовых клеток человека Институт стволовых клеток человека
ISKJ
774 M - - - russiaRussia
Ayala Pharmaceuticals Ayala Pharmaceuticals
AYLA
90 K - - $ 7.46 M israelIsrael
BioDelivery Sciences International BioDelivery Sciences International
BDSI
14 M - -4.8 % $ 255 M usaUSA
Aeterna Zentaris Aeterna Zentaris
AEZS
4.73 M - 5.93 % $ 314 M canadaCanada
BeiGene, Ltd. BeiGene, Ltd.
BGNE
3.22 B - 0.49 % $ 251 B cayman-islandsCayman-islands
Biogen Biogen
BIIB
12.4 B $ 195.13 -0.62 % $ 28.6 B usaUSA
BioMarin Pharmaceutical BioMarin Pharmaceutical
BMRN
1.34 B $ 62.62 -0.48 % $ 11.9 B usaUSA
Bellicum Pharmaceuticals Bellicum Pharmaceuticals
BLCM
500 - -9.72 % $ 5.89 M usaUSA
Baudax Bio Baudax Bio
BXRX
-1.24 M - 0.59 % $ 63 K usaUSA
Aptinyx Aptinyx
APTX
1.56 K - -39.0 % $ 4.57 M usaUSA
Aridis Pharmaceuticals Aridis Pharmaceuticals
ARDS
1 K - 17.91 % $ 11.1 M usaUSA
Amneal Pharmaceuticals Amneal Pharmaceuticals
AMRX
1.02 B $ 14.66 1.66 % $ 4.53 B usaUSA
Capricor Therapeutics Capricor Therapeutics
CAPR
310 $ 27.91 0.14 % $ 747 M usaUSA
CASI Pharmaceuticals CASI Pharmaceuticals
CASI
17.6 M $ 0.8 5.68 % $ 109 M usaUSA